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Abstract
Colorectal cancer (CRC) screening with a multitarget stool DNA test was recently approved by the Food and
Drug Administration. We used clinical effectiveness modeling to compare test intervals of 1, 3, or 5 years on
CRC incidence and related mortality to help inform screening guidelines. Our results showed that screening
every 3 years provides reasonable performance at acceptable cost.
Background: A multitarget stool DNA (mt-sDNA) test was recently approved for colorectal cancer (CRC) screening for
men and women, aged  50 years, at average risk of CRC. The guidelines currently recommend a 3-year interval for
mt-sDNA testing in the absence of empirical data. We used clinical effectiveness modeling to project decreases in
CRC incidence and related mortality associated with mt-sDNA screening to help inform interval setting.Materials and
Methods: The Archimedes model (Archimedes Inc., San Francisco, CA) was used to conduct a 5-arm, virtual, clinical
screening study of a population of 200,000 virtual individuals to compare the clinical effectiveness of mt-sDNA
screening at 1-, 3-, and 5-year intervals compared with colonoscopy at 10-year intervals and no screening for a 30-
year period. The study endpoints were the decrease in CRC incidence and related mortality of each strategy versus no
screening. Cost-effectiveness ratios (US dollars per quality-adjusted life year [QALY]) of mt-sDNA intervals were
calculated versus no screening. Results: Compared with 10-year colonoscopy, annual mt-sDNA testing produced
similar reductions in CRC incidence (65% vs. 63%) and related mortality (73% vs. 72%). mt-sDNA testing at 3-year
intervals reduced the CRC incidence by 57% and CRC mortality by 67%, and mt-sDNA testing at 5-year intervals
reduced the CRC incidence by 52% and CRC mortality by 62%. At an average price of $600 per test, the annual, 3-year,
and 5-year mt-sDNA screening costs would be $20,178, $11,313, and $7388 per QALY, respectively, compared with no
screening. Conclusion: These data suggest that screening every 3 years using a multitarget mt-sDNA test provides
reasonable performance at acceptable cost.
Clinical Colorectal Cancer, Vol. 15, No. 3, e65-74 ª 2015 The Authors. Published by Elsevier Inc. This is an open access article
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The current guideline from the US Preventive Services Task Force
recommends routine colorectal cancer (CRC) screening in individuals
with average risk beginning at age 50 years and continuing until age
75.1 Screening should then be individualized thereafter until age 85,1Exact Sciences Corporation, Madison, WI
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http://dx.doi.org/10.1016/j.clcc.2015.12.003depending on the individual’s overall health.1 Despite the universal
appreciation of the value of CRC screening and the availability of
multiple screening options, CRC screening rates have remained sub-
optimal.2 Optical colonoscopy, the reference method for all other
screening strategies, provides a direct pancolonic structural examina-
tion. Despite the effectiveness of colonoscopy, its usage in daily practice
remains limited. Some patients might not have access to it, and others
are reluctant or refuse the procedure; thus, compliance with colonos-
copy remains low.2,3 The colonoscopy results can also be affected by
the quality of the bowel preparatory process, colorectal anatomy, and
operator skill.4,5 Furthermore, previously available noninvasive tests
only assessed lesional bleeding, which, if present, can be erratic.
A simple, noninvasive, multitarget stool DNA (mt-sDNA)-based
screening test (Cologuard; Exact Sciences, Madison, WI) with muchClinical Colorectal Cancer September 2016 - e65
e66 -
Modeling Effect of Intertest Interval of Multitarget Stool DNA Testgreater sensitivity for the detection of both CRC and advanced
precancerous lesions was thus developed to improve both nonin-
vasive screening performance and screening compliance.6-8 Colo-
guard consists of quantitative molecular assays to detect aberrantly
methylated DNA (NDRG4 and BMP3) and DNA mutations
(KRAS) in stool plus a fecal hemoglobin immunoassay. It was
approved by the US Food and Drug Administration in August 2014
for screening men and women aged  50 years with an average risk
of CRC. The test results are analyzed using a logistic regression
algorithm with a predeﬁned cutoff value to provide a single
dichotomous “positive” or “negative” test result.7,8 Patients with
“positive” results are referred for diagnostic colonoscopy and pa-
tients with “negative” ﬁndings continue with the average-risk CRC
screening program and undergo screening again in the future.
The current guidelines recommend a 3-year interval for mt-
sDNA-based testing9,10; however, the optimal testing interval for
Cologuard is in development. In the absence of longitudinal data,
the Agency for Healthcare Research and Quality has recommended
modeling as the preferred method for setting initial test intervals,
given the length, size, and complexity of the prospective studies that
would be needed to address this question.11 Comprehensive CRC
disease state models mimic the known biology of CRC development
in relation to patient factors, screening, and treatment strategies and
can estimate clinical effectiveness by calculating the theoretical re-
ductions in CRC incidence and related mortality. Furthermore,
multiple screening strategies and intervals can be compared in real
time.
In the present study, we used clinical effectiveness modeling to
assess the projected decrease in CRC incidence and related mortalityFigure 1 The Archimedes Model. The Model Evaluates Virtual Peop
and/or Develop Symptoms, Seek Care, and Receive Diagn
Abbreviations: BMI ¼ body mass index; FOBT ¼ fecal occult blood test.
Clinical Colorectal Cancer September 2016with mt-sDNA-based CRC screening when used at 1-, 3-, and 5-
year screening intervals. We compared the projected decrease in
CRC incidence and related mortality to the rates with optical co-
lonoscopy performed every 10 years, the reference method.9,10 Our
ﬁndings provide quantitative modeling data to help support the
inclusion of mt-sDNA testing in CRC medical policy statements
and screening guidelines.
Materials and Methods
Model
The Archimedes model (Archimedes Inc., San Francisco, CA)
was used to conduct a 5-arm virtual clinical screening study
comparing the effect of 4 screening strategies (Cologuard at a 1-, 3-,
or 5-year interval or colonoscopy at a 10-year interval) versus “no
screening” (Figure 1; see also Supplemental Appendix 1 in the
online version).12 The Archimedes model is a largescale integrated
simulation model. Its core is a set of algebraic and differential
equations that represent physiology, disease states, and health care
processes (systems). The CRC submodel represents those aspects of
the anatomy and physiology pertinent to CRC and its
complications.
The Archimedes model was built with empirical data derived
from systematic published data searches in MEDLINE, Cochrane
Database of Systematic Reviews, PubMed, Web of Science, and
Google Scholar, supplemented with manual searches. CRC-speciﬁc
modeling data were derived from clinical trials, retrospective ana-
lyses, population surveys, and cancer registries, including colonos-
copy data from the Clinical Outcomes Research Initiative database
and clinical incidence data from the Surveillance Epidemiology andle, Who Can Experience ‡ 1 Disease States, Undergo Screening
osis and Treatment
Table 1 Effect of Screening Strategies on CRC Incidence and
Related Mortality Compared With No Screening
CRC
Screening
Strategy
Screening Age 50-85 Years
Decrease in
CRC Incidence
(%)
Decrease in
CRC Mortality
(%)
QALY Gained
Relative to No
Screening
No screening 0 0 0
Colonoscopy
every 10 years
65 73 0.1330
mt-sDNA annually 63 72 0.1290
mt-sDNA every 3
years
57 67 0.1160
mt-sDNA every 5
years
52 62 0.1050
Abbreviations: CRC ¼ colorectal cancer; QALY ¼ quality-adjusted life year; mt-sDNA ¼
multitarget stool DNA (test).
Barry M. Berger et alEnd Results program. This model has been validated in a similar
manner to other well-published CRC screening models used by the
Cancer Intervention and Surveillance Modeling Network con-
sortium, including MISCAN and simCRC (available at http://
cisnet.cancer.gov/proﬁles/), using the National Polyp Study, Min-
nesota FOBT (fecal occult blood test) Screening Trial, Cancer
Prevention Study II Nutrition Cohort, Women’s Health Study,
Women’s Health Initiative, UK Flexible Sigmoidoscopy Trial, and
Veterans Affairs Cooperative Study Group (see Supplemental
Appendix 1 in the online version).
The model creates a population of virtual individuals, each of
whom has a simulated physiology, experiences  1 disease states,
develops symptoms, seeks care, and is diagnosed and treated. The
virtual population is rendered representative of real people because it
uses genuine person-speciﬁc data from the National Health and
Nutrition Examination Survey. This ensures that the distributions
and correlations of all important variables are the same in the
simulated and actual populations. In our study, a population of
200,000 virtual individuals was assigned to 1 of 5 study arms for a
30-year period. Screening started at age 50 and ended at age 85,
with screening beneﬁts accruing until the virtual subject died or 30
years had elapsed from study entry.
The model includes 3 components: (1) a natural history
component that tracks adenoma development, growth, and pro-
gression to cancer and the development of any signs or symptoms as
a function of age, gender, race/ethnicity, obesity, physical activity,
and family history; (2) a screening component that allows for the
detection and removal of adenomas and the diagnosis of preclinical
(asymptomatic) CRC; and (3) a treatment component that predicts
survival after the diagnosis of CRC. The model accounts for
important risk factors for CRC, including age, gender, race, and
body mass index (Figure 1). Subject adherence was set at 100% for
all screening and follow-up tests.
Subjects and Screening Strategies
No Screening. In the control arm, subjects did not receive any
screening during the 30-year period (“no screening”). Individuals
developing advanced CRC precursor lesions or CRC were removed
from the screening pool.
mt-sDNA Screening. mt-sDNA screening performance data for
Cologuard were taken from a recently completed 10,000-patient,
multisite, screening study of average-risk patients.7 That study had
compared Cologuard with fecal immunochemical testing (FIT)
using colonoscopy of all subjects as the reference method.7 Colo-
guard sensitivity was 92% for CRC (American Joint Committee on
Cancer stages I-IV)7 and 66% for adenomas  2 cm and 42% for
adenomas  1 cm; the speciﬁcity was 87%.7 For the calculation of
speciﬁcity, true-positive cases included only subjects with CRC or
adenomas or sessile serrated polyps of  1 cm and those with ad-
enomas of any size with high-grade dysplasia or a villous component
of  25%.
In the model, subjects with “negative” Cologuard results were
screened again at 1-, 3-, or 5-year intervals until the end of the study
or until their test results turned “positive.” The subjects with
“positive” results were referred for diagnostic colonoscopy. The
subjects with positive (abnormal) ﬁndings on diagnosticcolonoscopy were treated or underwent colonoscopic surveillance
according to the current guidelines.10 Subjects with “negative”
ﬁndings on diagnostic colonoscopy were returned to the screening
pool after 10 years and continued with colonoscopy screening.7 A
Cologuard test cost of $600 was used in the model.
Colonoscopy. The colonoscopy performance characteristics were
derived from a review of the published data (see Supplemental
Appendix 2 in the online version) and included a sensitivity of
95% for CRC and 90% for adenomas  1 cm and a speciﬁcity of
90%.13 Subjects with abnormal ﬁndings on the screening colo-
noscopy were treated or underwent colonoscopic surveillance ac-
cording to the current guidelines. Subjects with “negative” ﬁndings
were returned to the screening pool after 10 years and continued
with colonoscopy screening. A colonoscopy cost of $1500 was used
in the model (see Supplemental Appendix 2 in the online version).
Endpoints. We used a decrease in CRC incidence and related
mortality as the clinical effectiveness endpoints for the modeled
strategies. In addition, cost-effectiveness ratios (CERs) in US dollars
per quality-adjusted life year ($/QALY) were calculated for each
modeled interval compared with no screening. The CERs were
calculated from a societal perspective using published data sources
for quality adjustments and cost (see Supplemental Appendix 2 in
the online version).
Results
The theoretical anticipated decrease in CRC incidence and
mortality resulting from each of the 4 different screening strategies
compared with the no screening control arm is listed in Table 1.
Compared with no screening, colonoscopy every 10 years was
associated with a 65% decrease in CRC incidence and a 73%
decrease in CRC-related mortality, with a gain of 0.1330 QALY.
Annual mt-sDNA testing with Cologuard was associated with a
63% decrease in CRC incidence and a 72% decrease in CRC-
related mortality, with a gain of 0.1290 QALY. Screening every 3
years with mt-sDNA testing was associated with a 57% decrease in
CRC incidence and a 67% decrease in CRC-related mortality, with
a gain of 0.1160 QALY. Finally, screening every 5 years withClinical Colorectal Cancer September 2016 - e67
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e68 -mt-sDNA testing was associated with a 52% decrease in CRC
incidence and a 62% decrease in CRC-related mortality, with a gain
of 0.1050 QALY.
Compared with no screening, screening every 1, 3, and 5 years
with Cologuard resulted in a CER of $20,178/QALY, $11,313/
QALY, and $7388/QALY, respectively (Table 2).
Discussion
We used the Archimedes CRC model to perform a virtual clinical
study to examine the theoretical clinical effectiveness of a new mt-
sDNA CRC screening test on reducing CRC incidence and related
mortality. We compared the differential clinical effectiveness of
Cologuard when used at 1-, 3-, and 5-year intervals with no
screening and with colonoscopy every 10 years and calculated the
cost-effectiveness of each interval and colonoscopy every 10 years
compared with no screening.
Setting an effective and achievable test interval depends on both
the performance of the screening test and the ability of patients,
clinicians, and administrative infrastructures to maintain the rec-
ommended schedule. Our modeling results suggest that annual
Cologuard testing would provide a reduction in CRC incidence and
mortality similar to that of colonoscopy every 10 years. However,
clinical experience has indicated that adherence to annual CRC
screening (with fecal occult blood testing or FIT) is low in both
clinical practice14-19 and clinical trial settings.20 Gellad et al14 re-
ported only 13% to 14% adherence to consecutive annual fecal
occult blood testing during a 4- to 5-year period in an integrated
Veterans Affairs health system supported by an electronic medical
record. Improvement in adherence rates is possible with aggressive
clinical and administrative management. For example, a highly in-
tegrated private health care delivery system supported by a centralTable 2 CERsa of mt-sDNA Screening at Intervals of 1, 3, and
5 Years Compared With No Screening and in Relation
to Other Cancer Screening Tests With No Screening
Comparators
Variable CER ($/QALY)
CRC screening strategy
No screening $0
mt-sDNA annually $20,178
mt-sDNA every 3 years $11,313
mt-sDNA every 5 years $7388
Cervical (Papanicolaou smear) and
breast cancer (mammography)
screening strategy
Pap smear, annual24 $23,900
Pap smear, triennial24 $15,500
Mammography, biennial,
aged 50-75 years25
$30,000
Mammography, biennial,
age 40-80 years25
$32,307
Mammography, annual,
age 40-80 years25
$39,210
Abbreviations: CERs ¼ cost-effectiveness ratios; CRC ¼ colorectal cancer; QALY ¼
quality-adjusted life-year; mt-sDNA ¼ multitarget stool DNA (test).
aCER expressed as US dollars/QALY.
Clinical Colorectal Cancer September 2016electronic medical record achieved 50% to 60% adherence with
annual, single-sample FIT testing with a 5-year follow-up period.21
However, this system requires signiﬁcant resources. In primary care
environments that lack direct patient call centers, electronic medical
recordebased reminders, and tracking systems and have limited
ofﬁce staff, annual screening might not be achievable. Furthermore,
few patients prefer annual testing.22
The greater point sensitivity of Cologuard relative to FIT for the
detection of CRC (92.3% vs. 72.7%) and advanced precancerous
lesions (42.4% vs. 23.8%) supports a less-frequent screening in-
terval for Cologuard than for FIT.7 Screening at a less-frequent
interval also has the potential to increase adherence, which could
also serve to decrease the burden on both patients and physician
practices. Our modeling results showed that testing every 3 years
with Cologuard provided sufﬁcient clinical effectiveness for the
detection of CRC, decreasing the CRC incidence by 57% and
reducing CRC-related mortality by 67%. Although a 5-year Colo-
guard test interval could further lower the clinical and administra-
tive burden of testing, the clinical effectiveness was substantially
lower than that of colonoscopy every 10 years.
Screening study data7 have similarly supported a Cologuard
multiyear interval with a negative predictive value of a single test
event of 99.94% for CRC and 95% for advanced adenoma. These
data suggest that the presence of missed signiﬁcant lesions before the
next scheduled screening event would be rare.
We also assessed the cost-effectiveness of Cologuard at various
intervals relative to no screening to examine the economic accept-
ability of each screening interval. The CERs of mt-sDNA screening
performed every 1, 3, or 5 years compared with no screening were
all cost-effective relative to a conservative willingness-to-pay
threshold of $25,000/QALY.23 All modeled Cologuard and colo-
noscopy screening CERs compared favorably with those of other
common cancer screening tests that have been compared with a no
screening strategy, including annual or triennial Papanicolaou
smears24 ($23,900/QALY and $15,500/QALY, respectively) and
mammography ($30,000/QALY biennial for women aged 50-75
years, $32,307/QALY biennial for women aged 40-80 years, and
$39,210/QALY annual for women aged 40-80 years; Table 2).25
The use of CERs compared with no intervention allows for com-
parisons of a broad range of medical interventions deemed of so-
cietal beneﬁt. Modeling studies using empirical data to explore the
effect of differential adherence of CRC screening strategies will be
important in examining incremental cost-effectiveness ratios
(ICERs) in CRC screening.
The primary focus of the present analysis was to evaluate the
intertest interval for mt-sDNA testing as a screening option for CRC.
Colonoscopy remains the reference standard for CRC screening. We
did not consider ICER modeling across a broad range of CRC
screening tests, because the utility of the ICER is limited by the
assumption that all tests will be equally acceptable to patients. This
mt-sDNA test was developed precisely because colonoscopy is un-
acceptable to a subset of patients. Patient preference plays a strong role
in CRC screening uptake and adherence and thus on the achievable
performance of the screening program. Patient preference can be
driven by various factors, including test accuracy, test frequency, and
the invasiveness of the text. Some patients prefer the most accurate
test, but others will prefer the least invasive and others the least
Supplemental Data
The supplemental data accompanying this article can be found in
the online version at http://dx.doi.org.10.1016/j.clcc.2015.12.003.
Barry M. Berger et alfrequent.19,22 Although colonoscopy is the most accurate and least
frequent CRC screening method, it is also the most invasive, neces-
sitates a time commitment from patients (including the potential for
missed work), and requires preprocedure bowel preparation, sedation
during the procedure, and a chaperone for transport after the proce-
dure.10Colonoscopy can also be associatedwith complications such as
perforation and postpolypectomy bleeding.10 In contrast, mt-sDNA
testing is less invasive but is also less sensitive than colonoscopy and
requires patient cooperation for home sample collection. Thus, we did
not view mt-sDNA and colonoscopy as having equal acceptability for
patients undergoing CRC screening but rather as compatible
screening options for different patient archetypes.
Approximately 35% of the population aged 50 to 75 years who are
eligible for CRC screening remain unscreened,2 despite the avail-
ability of multiple CRC screening tests and physician recommenda-
tions for screening. In particular, the compliance rates with
colonoscopy have remained low.2,3 Inadomi et al15 found that only
38% of subjects recommended for colonoscopy actually completed
the screening within 12 months. However, a subset of patients might
be willing to be screened using other, less-invasive tests (eg, mt-sDNA
testing) who otherwise might not be willing to undergo screening.
This was suggested by the results from Berger et al,26 who reported
that 52% of subjects who used an earlier, less-sensitive mt-sDNA test
had never previously undergone screening. A sensitive test that is
noninvasive and has an acceptable CER compared with no screening
could provide an important alternative for patients who have refused
other CRC screening modalities such as colonoscopy.
The present study was limited by several factors. First, the model
assumed 100% adherence for all screening strategies during a 30-
year period aged 50 to 85 years. Clinical experience suggests that
patient acceptance of, and adherence to, different screening strate-
gies will be dependent on many factors and variables. The model
output, therefore, might have overestimated the actual clinical
beneﬁt of CRC screening strategies with respect to CRC incidence
and mortality reduction. Second, recent observations and insights
into the biology of colorectal carcinogenesis27 and the performance
of colonoscopy, in general,4,5,27 and on proximal versus distal
advanced colorectal neoplasia, in particular,28-31 have not yet been
incorporated into currently published CRC disease state models,
which could affect the model outcomes. Third, with respect to cost-
effectiveness, the cost of colonoscopy varies signiﬁcantly across
providers and payors, and the cost used in our model might not
reﬂect the cost for a speciﬁc payor. Similarly, the cost of therapy will
continue to increase over time with the increased use of biologic
agents and the migration of postoperative chemotherapy to lower
stage disease. The cost used in our model might have under-
estimated the cost of treatment and therefore underestimated the
screening cost-effectiveness.
Conclusion
The present modeling study assessed the effect of the screening
interval for mt-sDNA testing with Cologuard on CRC incidence
and related mortality. The modeled results showed that a 3-year
mt-sDNA test interval provides a decrease in CRC incidence
and mortality that is lower than that of colonoscopy every 10 years
during a 30-year screening period but still clinically acceptable
and cost-effective at a $25,000/QALY willingness-to-paythreshold. Although the screening performance of a 3-year inter-
val was less effective than an annual interval, it is likely to be more
achievable because of clinical practice and patient preference
factors and the greater cost-effectiveness. A 5-year interval was
more cost-effective than the 3-year interval but sacriﬁced addi-
tional performance. A 3-year Cologuard test interval seems to
provide reasonable performance at acceptable costs with a lower
patient, clinician, and administrative burden than annual
screening and with improved clinical performance compared with
5-year screening. These results support the current expert opin-
ionebased recommendation of a 3-year screening interval for
sDNA according to the American College of Gastroenterology9
and the Centers for Medicare and and mt-sDNA as per the
American Cancer Society32 guidelines and the Centers for
Medicare and Medicare Services coverage policy.33
Clinical Practice Points
 The Food and Drug Administration recently approved mt-
sDNA testing for CRC screening.
 The current guidelines recommend a 3-year interval for mt-
sDNA screening but without empirical data available.
 A virtual clinical study using modeling examined the clinical
effect of 1-, 3-, and 5-year intervals.
 A 3-year interval appeared to be clinically effective at reasonable
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Appendix 1: The Archimedes Model
The Archimedes model is a largescale, integrated simulation
model of human physiology, diseases, and health care delivery
processes that includes a colorectal cancer (CRC) submodel.1,2 The
model core is a set of algebraic and differential equations that
represent physiology, disease states, and health care processes (sys-
tems). The CRC submodel represents those aspects of the anatomy
and physiology pertinent to CRC and its complications. The
Archimedes model creates virtual people, each of whom has a
simulated physiology and can experience  1 disease states, develop
symptoms, seek care, and receive diagnosis and treatment. Virtual
people are rendered representative of real people with actual person-
speciﬁc data from the National Health and Nutrition Examination
Survey. The methods for creating copies ensure that the distribu-
tions and correlations of all important variables in the simulated
population are the same as those in the real population.
The CRC submodel, developed in collaboration with the
American Cancer Society and an expert panel, was built with
empiric data derived from systematic published data searches in
MEDLINE, Cochrane Database of Systematic Reviews, PubMed,
Web of Science, and Google Scholar, supplemented with manual
reference searches. CRC-speciﬁc modeling data were derived from
clinical trials, retrospective analyses, population surveys, and cancer
registries. The model also includes individual-level colonoscopy data
from the Clinical Outcomes Research Initiative database3 and
clinical incidence data from the Surveillance Epidemiology and End
Results program.4
The model includes (1) a natural history component that tracks
adenoma development, growth and progression to cancer, and the
development of any signs or symptoms as a function of age, gender,
race/ethnicity, obesity, physical activity, and family history; (2) a
screening component that allows for the detection and removal of
adenomas and the diagnosis of preclinical (asymptomatic) CRC;
and (3) a treatment component that predicts survival after the
diagnosis of CRC. The model accounts for important risk factors of
CRC, including age, gender, race, and body mass index.
Both non-neoplastic polyps (hyperplastic polyps) and neoplastic
polyps (conventional adenomas and sessile serrated adenomas
[SSAs]) with the potential to progress to CRC are modeled. By
modeling both types, the precision of the model can be compared
with empirical data sources for validation.
In the model, polyps arise in the colon and the rectum sto-
chastically through a nonhomogenous Poisson process.5 The inci-
dence of polyps increases with age and is a function of the
aforementioned risk factors. Polyps can occur at 8 different
anatomic sites: cecum, ascending colon, hepatic ﬂexure, transverse
colon, splenic ﬂexure (collectively, the “right” or proximal colon),
descending colon, sigmoid colon, and rectum (collectively the “left”
or distal colon). The growth of hyperplastic polyps and adenomas is
modeled using a log-linear equation. As an adenoma grows, its
histologic features and grade will worsen. On average, conventional
adenomas and SSAs are larger than hyperplastic polyps. The pro-
pensity of an adenoma to become cancerous is assumed to be a
function of age and adenoma type, size, and location. Once an
adenoma becomes cancerous, it will grow exponentially, with a
doubling time derived from a meta-analysis of the published data.6-9
When it reaches a certain size, the patient will begin to experience CRC
signs or symptoms and, after a delay period, will be diagnosed by the
health care system with symptomatic CRC. The distribution of CRC
size at diagnosis of symptomatic CRC has been derived from early
Surveillance Epidemiology and End Results (SEER) data4 to minimize
the effects of screening. If the patient undergoes screening, the CRC
will be detectable earlier, before symptoms develop. The performance
of a test (ie, FIT, stool DNA [sDNA], or colonoscopy) depends on the
size, type, and location of polyps.
The CRC outcomes predicted by the Archimedes model have
been validated against several studies, including the National Polyp
Study,10 Minnesota FOBT (fecal occult blood test) Screening
Trial,11 Cancer Prevention Study II Nutrition Cohort,12 Women’s
Health Study,13 Women’s Health Initiative,14 UK Flexible
Sigmoidoscopy Trial,15 and Veterans Affairs Cooperative Study
Group.16
Screening Simulation Setup
The effectiveness of CRC screening by multitarget sDNA test (3
intervals) and colonoscopy every 10 years was compared by con-
ducting a virtual trial, which subjected a population of virtual in-
dividuals to different trial arms (screening strategies). For each
strategy, screening started at age 50 years, ended at 85 years, and
had the compliance set at 100% (ie, 100% rate of adoption) for all
arms, except for the control arm (no screening). Patients with
positive (abnormal) results by multitarget sDNA testing underwent
diagnostic colonoscopy at 100% compliance. Those found to have
developed precursor lesions, advanced adenomas (adenomas  1 cm
or with high-grade dysplasia or  25% villous component of any
size), or CRC were removed from the screening pool. For this ex-
ercise, those patients with small, nonadvanced adenomas (< 1 cm)
were treated similarly to the treatment of patients with negative
(normal) ﬁndings, remained in the screening, pool and were
screened thereafter using colonoscopy after the 10-year colonoscopy
intertest interval had elapsed.
An estimate of cost-effectiveness was also undertaken to provide
economic context. The cost-effectiveness ratio (CER) of CRC
screening with multitarget sDNA strategies ($600/test) compared
with no screening was determined. A low willingness-to-pay
threshold of $25,000 was considered cost-effective.
Cost of CRC Treatment
The CRC treatment costs were adapted from estimates based on
data from the SEER and published sources.17 Cancer treatment
costs are divided into 3 phases: initial, continuing, and ﬁnal phases.
The initial phase of care is deﬁned as the ﬁrst 12 months after the
diagnosis, the last-year-of-life phase is the ﬁnal 12 months of life,
and the continuing phase is all the months between the initial and
last-year-of-life phases. For patients who survive < 24 months after
diagnosis, the ﬁnal 12 months of observation and costs of care were
allocated ﬁrst to the last-year-of-life phase, because the content of
care for patients with short survival will more similar to the last-
year-of-life phase than to the initial phase. The remaining months
of observation and costs were allocated to the initial phase, with no
contribution to the continuing phase. The cancer-related costs in
the continuing phase were an annual estimate.
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All costs were adjusted to 2010 values using the medical care
component of the Bureau of Labor Statistics Consumer Price In-
dex.18 The health utility scores for different the CRC outcomes
were derived from Ness et al.19 For each sDNA strategy, the CER
was calculated compared with no screening.
Quality-of-life Adjustments for CRC Diagnosis
The quality-of-life parameters for the calculation of quality-
adjusted life years were derived from the published data19 and are
reported in Table 1.
Perspective
A societal perspective was used, with costs, beneﬁts, and life years
discounted 3% and with adherence to other recommendations of
the Panel on Cost-Effectiveness in Health and Medicine.20 The
effects of discount rate, patient adherence, and cost of colonoscopy
on the cost-effectiveness of the CRC screening strategies through
sensitivity analysis were explored.
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Appendix 2 Archimedes Model Assumptions
Parameter Assumptions and Approaches
Natural history of CRC
Polyp type Three major types of polyps were modeled: HPs, conventional adenomas, and SSAs
Adenoma incidence Adenoma incidence was assumed to follow a nonhomogenous Poisson distribution1
Effects of gender, family history, BMI, aspirin, hormonal replacement therapy, and diabetes on incidence of HPs, conventional
adenomas, and SSAs represented by HRs derived from author-conducted meta-analyses2-30
Adenoma growth Growth of adenomas described with a Gompertzian growth equation; at initiation, adenoma size was assumed to be 1 mm
Adenoma growth rate was modeled as a function of age, gender, and race and calibrated to CORI data and other published
colonoscopy screening studies31-41
Size distribution of HPs, conventional adenomas, and SSAs at colonoscopy was matched to the CORI database and meta-analysis
of published studies30,42-46
Adenoma location Adenomas can occur at 8 different anatomic sites along the colon and rectum (ie, cecum, ascending colon, hepatic ﬂexure,
transverse colon, splenic ﬂexure, descending colon, sigmoid colon, and rectum)
Distribution of anatomic sites of conventional adenomas and HPs as a function of age and gender were extracted from the CORI database
and were consistent with the published data47,48; distribution of SSAs was based on a meta-analysis4,30,42,49
Adenoma histologic features and
dysplasia grade
Histologic features and grade of dysplasia are functions of adenoma size and were determined from an author-conducted
meta-analysis3,50-53
Cancer risk and malignant transformation Hazard rate of an adenoma becoming malignant is a function of age, gender, and adenoma location
The form of the hazard rate was derived from an author-conducted meta-analysis41,54-57; the parameters were obtained by ﬁtting
the hazard rate to the CORI and SEER databases
Cancer progression Progression of tumors from stage 0 to IV was calibrated to SEER data and stage distribution data obtained from screening studies58-62
Cancer diagnosis and survival Patient survival is a function of age and tumor characteristics at diagnosis and was derived from the SEER database
Effect of diabetes on CRC-speciﬁc survival was modeled using data from a meta-analysis
Test characteristics
Colonoscopy CRC 95% sensitivity (range, 90%-99%)
Adenoma by size
0-5 mm: 70% sensitivity (range, 65%-75%)
5-10 mm: 80% sensitivity (range, 75%-85%)
 10 mm: 90% sensitivity (range, 85%-95%)
CRC and advanced adenoma: 95% speciﬁcity
Completion rate: 97%
Proximal lesions: 75%63
Miss rate for SSAs: 50% (indirect evidence of SSA prevalence and detection rates in colonoscopy screening studies)
Adverse events associated with
colonoscopy
Perforation and surgical mortality are a function of age and comorbidities and were derived from author-conducted meta-analysis
Costs
Colonoscopy without polypectomy $150064
Colonoscopy with polypectomy or
biopsy
$170064
CRC treatment CRC treatment costs were estimated for initial, maintenance, and terminal phases, including costs of targeted therapies
Disease stage Initial Maintenance Terminal
I $34,963 $2921 $136,514
II $48,417 $2728 $136,242
III $97,324 $3962 $139,979
IV $97,324 $12,707 $162,877
Treatment and prevention of other
diseases, including DM complications and
CVDs
Medication costs were obtained from drugstore.com as of April 2009
All other costs (eg, emergency visits, ofﬁce visits and admissions, and procedures) were based on 2007 Medicare reimbursement rates
Health utility
CRC stage65 Health disutility for colorectal cancer
I 0.74
II 0.67
III 0.50
IV 0.25
Other diseases Utility scores used: Sullivan and Ghushchyan29,30
Abbreviations: BMI ¼ body mass index; CORI ¼ Clinical Outcomes Research Initiative; CRC ¼ colorectal cancer; CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HP ¼ hyperplastic polyp;
HR ¼ hazard ratio; SEER ¼ Surveillance Epidemiology and End Results; SSA ¼ sessile serrated adenoma.
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